Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs

Abstract

A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions.

What is claimed is:  
     
         1 . A composition comprising a polypeptide at least 90% identical to a member selected from the group consisting of 
 (i) amino acids 21-480 of SEQ ID NO: 6,    (ii) amino acids 20-819 of SEQ ID NO: 8, and    (iii) amino acids 20-819 of SEQ ID NO: 10,    wherein said member is in a pharmaceutically acceptable carrier in an amount effective to elicit production of an antibody that binds to  S. pneumoniae  when said composition is administered to a mammal.    
     
     
         2 . The composition of  claim 1  wherein said percent identity is at least 95%.  
     
     
         3 . The composition of  claim 1  wherein said percent identity is at least 97%.  
     
     
         4 . The composition of  claim 1  wherein said polypeptide has the sequence of amino acids 21-480 of SEQ ID NO: 6.  
     
     
         5 . The composition of  claim 1  wherein said polypeptide has the sequence of amino acids 20-819 of SEQ ID NO: 8.  
     
     
         6 . The composition of  claim 1  wherein said polypeptide has the sequence of amino acids 20-819 of SEQ ID NO: 10,  
     
     
         7 . A composition comprising an active fragment of a polypeptide selected from the group consisting of: 
 (i) amino acids 21-480 of SEQ ID NO: 6,    (ii) amino acids 20-819 of SEQ ID NO: 8, and    (iii) amino acids 20-819 of SEQ ID NO: 10,    wherein said active fragment comprises at least about 10% and no more than about 85% of said polypeptide, wherein said active fragment comprises at least one histidine triad and at least one coiled coil region and wherein said active fragment is in a pharmaceutically acceptable carrier in an amount effective to elicit production of an antibody that binds to  S. pneumoniae  when said composition is administered to a mammal.    
     
     
         8 . The composition of  claim 7  wherein said active fragment further comprises at least 2 histidine triad regions.  
     
     
         9 . The composition of  claim 7  wherein said active fragment further comprises at least 2 coiled coil regions.  
     
     
         10 . A vaccine comprising a polypeptide containing the sequence of amino acids 21-480 of SEQ ID NO: 6 in a pharmaceutically acceptable carrier in an amount effective to protect against pneumococcal infection when administered to a mammal.  
     
     
         11 . A vaccine comprising a polypeptide containing the sequence of amino acids 20-819 of SEQ ID NO: 8 in a pharmaceutically acceptable carrier in an amount effective to protect against pneumococcal infection when administered to a mammal.  
     
     
         12 . A vaccine comprising a polypeptide containing the sequence of amino acids 20-819 of SEQ ID NO: 10 in a pharmaceutically acceptable carrier in an amount effective to protect against pneumococcal infection when administered to a mammal.  
     
     
         13 . A process for preventing infection caused by  S. pneumoniae  comprising administering the vaccine of  claim 10 .  
     
     
         14 . A process for preventing infection caused by  S. pneumoniae  comprising administering the vaccine of  claim 11 .  
     
     
         15 . A process for preventing infection caused by  S. pneumoniae  comprising administering the vaccine of  claim 12 .  
     
     
         16 . A process for preventing infection caused by  S. pneumoniae  comprising administering the composition of  claim 1 .  
     
     
         17 . An isolated polypeptide at least 95% identical to a member selected from the group consisting of 
 (i) amino acids 21-480 of SEQ ID NO: 6,    (ii) amino acids 20-819 of SEQ ID NO: 8, and    (iii) amino acids 20-819 of SEQ ID NO: 10,    wherein said polypeptide binds to an antibody that binds to  S. pneumoniae.      
     
     
         18 . The isolated polypeptide of  claim 17  wherein said percent identity is at least 95%.  
     
     
         19 . The isolated polypeptide of  claim 17  wherein said percent identity is at least 97%.  
     
     
         20 . The isolated polypeptide of  claim 17  wherein said isolated polypeptide has the amino acid sequence of said member.  
     
     
         21 . A composition comprising at least one antibody that binds to a polypeptide comprising an amino acid sequence at least 90% identical to a member selected from the group consisting of: 
 (i) amino acids 20-838 of SEQ ID NO: 4,    (ii) amino acids 21-480 of SEQ ID NO: 6,    (iii) amino acids 20-819 of SEQ ID NO: 8, and    (iv) amino acids 20-819 of SEQ ID NO: 10,    wherein said antibody is in a pharmaceutically acceptable carrier.    
     
     
         22 . The composition of  claim 21  wherein the antibody is the antibody against the polypeptide in (i).  
     
     
         23 . The composition of  claim 21  wherein the antibody is the antibody against the fragment in (ii).  
     
     
         24 . The composition of  claim 21  wherein the antibody is the antibody against the polypeptide in (iii).  
     
     
         25 . The composition of  claim 21  wherein the antibody is the antibody against the polypeptide in (iv).  
     
     
         26 . A composition comprising at least one antibody that binds to an active fragment of a polypeptide comprising a member selected from the group consisting of: 
 (i) amino acids 20-838 of SEQ ID NO: 4,    (ii) amino acids 21-480 of SEQ ID NO: 6,    (iii) amino acids 20-819 of SEQ ID NO: 8, and    (iv) amino acids 20-819 of SEQ ID NO: 10,    wherein said active fragment comprises at least about 10% and no more than about 85% of said polypeptide, wherein said active fragment comprises at least one histidine triad and at least one coiled coil region and wherein said active fragment is in a pharmaceutically acceptable carrier in an amount effective to elicit production of an antibody that binds to  S. pneumoniae  when said composition is administered to a mammal.    
     
     
         27 . A process for treating or preventing infection caused by  S. pneumoniae  comprising administering to a mammal afflicted with said ifection, or at risk of said infection, an effective amount of the composition of  claim 21 .  
     
     
         28 . A process for treating or preventing infection caused by  S. pneumoniae  comprising administering to a mammal afflicted with said ifection, or at risk of said infection, an effective amount of the composition of  claim 27.